Aegle Therapeutics is conducting a Phase 1/2A, non-randomized, multi-center, ascending dose, study to assess the effectiveness and safety of AGLE-102 on lesions in subjects with Recessive Dystrophic Epidermolysis Bullosa (RDEB).
AGLE-102 is a topical agent composed of native extracellular vesicles (EVs) derived from donor mesenchymal stem cells (MSCs) - special cells in your body that can act like repair crews and have the power to help fix and regenerate different tissues.
The aim of the study is to assess the safety and efficacy of AGLE-102 in the treatment of lesions in subjects with RDEB.
Compensation to support travel to the clinical trial site will be offered.
- Confirmed diagnosis of DEB as determined by electron microscopy, immunomapping, or genetic testing.
- The first 2 participants must be >18 years of age. Enrollment is projected to include participants >6 years of age in the 2nd quarter of 2024.
- Have one or more active wounds (unroofed EB erosions) each between 10 and 50 cm2 on arms, legs, or trunk.
Visit clinicaltrials.gov for a full list of inclusion and exclusion criteria.
If you have questions regarding the RDEB AGLE-102 Clinical Trial, or if you are interested in participating, please contact:
Contact:
- Mei Chen, PhD
- Phone: (323) 865-0621
- Email: chenm@usc.edu
Locations:
- University of Southern California. Compensation for travel will be provided.
- Additional sites will be coming mid 2024.
See the AGLE-102 informational brochure
